Advanced Transdermal Technologies

We are Skin Experts

Want To Explore A Transdermal Opportunity? We Can Help.

Contact Us
Advanced Transdermal Technologies

We Develop

For You

Transdermal Drug Delivery, From Concept To Scale-Up.

Technology
Advanced Transdermal Technologies

CDMO Pharma Company

We Specialize In Tailored Drug Delivery Systems. Agile, Reliable, And Globally Certified.

Our Products
- About Amarin-

Amarin in Numbers

Trusting the development of generic patches to Amarin team increases the chances of obtaining a superior patch compared to the reference product.

208+
Markets
35M
Developments
100%
Batchs

Explore our portfolio and learn how our patches provide greater efficiency, lower costs and a longer shelf life of the patch.

Portfolio
- Our Values-

Our way of working

Reliableness

We build long-term, transparent relationships with our partners and clients. Trust and clarity are at the heart of everything we do.

Flexibility

As a niche player, we adapt to our partners’ needs, offering tailor-made solutions that support project development at every stage.

Passion

Our passion drives our work. It is the energy that on daily basis fuels innovation, teamwork, and the pursuit of better solutions.

Commitment

We honor our word. With responsibility and dedication, we stay true to our goals and clients, proven by our history and trusted partnerships.

30+ Years Developing Customized Drug Delivery Solutions For Global Markets. Find out more About Our Services

- our history -

Amarin Legacy

1983

Amarin is an Argentine company established in the City of Buenos Aires

1990

Estradiol TDS licensed and supplied to Wyeth Ayerst in Latam for more than 10 years

1999

TDS Technology Transfer to Indian Company Zydus Cadila

2000

Analgesic patch developed by Amarin

2007

Analgesic patch exports from Argentina to EU began

2010

Helm AG became a shareholder and marketing agent for Amarin

2011

Formulations and manufacturing of analgesic patch transferred to EU (LTS & IBSA)

2016

Patches for cronic pain and dementia associated with Parkinson out-licensed to a multinational company in Latam

2017

Built up our own manufacturing plant

2018

Diclofenac sodium 1% gel developed by Amarin and approved by US FDA

2019

Patches for dementia associated with Parkinson: launched in Argentinean market and with successful results on a BE Study performed in Brazil.

2019

Mercosur certification achieved, including ANVISA approval

2021

First international exports of our patches for cronic pain. .

2023

Successful market launch of our patches for cronic pain.

2023

Expansion into Oral Films technology.

2024

Facility upgrade with new HPLC systems.

2025

Start of exports to global markets for our patches for cronic pain.
Words from our CEO, Sergio Lucero
- FAQ -

What do you want to know?

Not all molecules are suitable. Feasibility depends on size and properties. At Amarin, we identify which can be effectively transformed into patches or gels.

We offer three models: out-licensing -with ready to sell portfolio-, development under contract and co-development where we advance projects before partnering for clinical programs and commercialization.

Yes. Our products are tested under ICH climatic zones. We cover Zone II (U.S., Europe) and Zone IVb (hot, humid regions), ensuring stability and global regulatory compliance. commercialization.

- Do you have questions? -

Contact Us

    - meet specialist -

    expert doctor and lab assistant

    - Recent projects -

    Some of our research

    Click Here

    Blood Sugar Test

    Laboratory Test

    Food Research

    Laboratory Test

    Soil Test Research

    Laboratory Test

    Virus & Bacteria

    Laboratory Test

    Virus & Bacteria

    Laboratory Test
    - Our Testimonial -

    What clients say about us.

    Lorem Ipsum has been the industry standard dummy text ever since of type and scrambled make a type specimen book it has survived not.

    Dr. Rosana Kaun

    Business Manager
    Lorem Ipsum has been the industry standard dummy text ever since of type and scrambled make a type specimen book it has survived not.

    Dr. Rosana Kaun

    Business Manager
    Lorem Ipsum has been the industry standard dummy text ever since of type and scrambled make a type specimen book it has survived not.

    Dr. Rosana Kaun

    Business Manager
    Lorem Ipsum has been the industry standard dummy text ever since of type and scrambled make a type specimen book it has survived not.

    Dr. Rosana Kaun

    Business Manager
    - LATEST NEWS AND ARTICLE -

    Latest news and articles from Amarin.

    View All Post